Literature DB >> 8913404

Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors.

P V Dicpinigaitis1.   

Abstract

OBJECTIVE: To determine whether baclofen can suppress the cough induced by angiotensin-converting enzyme (ACE) inhibitors.
DESIGN: Prospective, open-label, clinical trial of a 4-week course of low-dose oral baclofen (5 mg tid days 1-7, 10 mg tid days 8-28).
SUBJECTS: Seven patients with severe, persistent ACE inhibitor-induced cough.
SETTING: University-affiliated teaching hospital. MAIN OUTCOME MEASURES: Study participants kept daily diaries monitoring the frequency of cough during and after completion of baclofen therapy.
RESULTS: All subjects demonstrated diminution of cough after initiation of baclofen. Initial improvement was noted by a mean of 4.0 days (range 3-6), and maximal improvement during treatment was achieved by a mean of 10.7 days (range 5-15). In addition, all subjects demonstrated persistent suppression of cough (range 25-74 d) after discontinuation of the study drug.
CONCLUSIONS: Low-dose oral baclofen therapy caused a prolonged antitussive effect in all subjects without inducing any adverse reactions. Baclofen may offer an alternative to the discontinuation of ACE inhibitor therapy in patients for whom these drugs are required.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913404     DOI: 10.1177/106002809603001106

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  9 in total

Review 1.  Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines.

Authors:  Donald C Bolser
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

2.  Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors.

Authors:  Seyed H Mahmoudpour; Abirami Veluchamy; Moneeza K Siddiqui; Folkert W Asselbergs; Patrick C Souverein; Catherine E de Keyser; Albert Hofman; Chim C Lang; Alexander S F Doney; Bruno H Stricker; Anthonius de Boer; Anke H Maitland-van der Zee; Colin N A Palmer
Journal:  Pharmacogenet Genomics       Date:  2017-03       Impact factor: 2.089

Review 3.  Central mechanisms II: pharmacology of brainstem pathways.

Authors:  D C Bolser
Journal:  Handb Exp Pharmacol       Date:  2009

Review 4.  Current and future centrally acting antitussives.

Authors:  Donald C Bolser
Journal:  Respir Physiol Neurobiol       Date:  2006-03-06       Impact factor: 1.931

5.  Antitussive effects of the peripherally restricted GABAB receptor agonist lesogaberan in guinea pigs: comparison to baclofen and other GABAB receptor-selective agonists.

Authors:  Brendan J Canning; Nanako Mori; Anders Lehmann
Journal:  Cough       Date:  2012-10-01

6.  Zofenopril and incidence of cough: a review of published and unpublished data.

Authors:  Stefano Omboni; Claudio Borghi
Journal:  Ther Clin Risk Manag       Date:  2011-11-29       Impact factor: 2.423

7.  Successful resolution of refractory chronic cough induced by gastroesophageal reflux with treatment of baclofen.

Authors:  Xianghuai Xu; Qiang Chen; Siwei Liang; Hanjing Lü; Zhongmin Qiu
Journal:  Cough       Date:  2012-10-18

Review 8.  Acute cough in the elderly: aetiology, diagnosis and therapy.

Authors:  John Widdicombe; Shankar Kamath
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  Peripheral mechanisms II: the pharmacology of peripherally active antitussive drugs.

Authors:  D Spina; I McFadzean; F K R Bertram; C P Page
Journal:  Handb Exp Pharmacol       Date:  2009
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.